Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Clonal Cytopenia of Undetermined Significance 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × canakinumab × Clear all
NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
41 enrolled
Thoracic

Lung Neoplasms

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡